English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NA /

2021-0704

Safety Of Switching From Intravenous Daratumumab To Subcutaneous Daratumumab In Patients With Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
NA
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: